Fed Chair Empowers Weekly Stock Market Continuation – $ADT $AMC $FATE $HL $KDNY $TSLA $XBI Rise!
- Published Dec 03, 2022
- Agriculture & Energy
- Atossa Therapeutics, Inc.
- Biotech & Healthcare
- Consumer Goods & Trends
- Current Coverage
- Disney
- Fate Therapeutics, Inc.
- Financials & Fintech
- InMed Pharmaceuticals Inc.
- Investing & Inspiration
- INVO Bioscience
- Market News
- Materials & Natural Resources
- Technology & Beyond
- Tesla
Happy Saturday All!
I hope you ll had a great week and enjoyed the balance of the group stage of the 2022 World Cup. Congratulations to Team USA that is now scheduled to play Netherlands in the knock out stage as you are receiving this message this fine Saturday.
As for the markets this week, investors realized positive continuation after last week’s solid rebound. Did you know that the Dow is now up a whopping 20% from its October low?
Continuing to fuel these moves, the macroeconomic schedule produced another set of reports this week that continued to give investors, and now the Fed, the impression that the skyrocketing interest rate process of 2022 is beginning to cause the desired slowdown effect and that we my be beginning to win the fight against inflation. In fact, this week Fed Chair “Uncle Jerry” Powell offered a message that embraced a more moderate go-forward approach for interest rate raises and left all with the impression that a 50 basis point raise was on the docket for December and not the 75 basis point that had been expected. The schedule included on Tuesday, the September FHFA Housing Price Index report that came in higher at .1%, the September S&P Case-Shiller Home Price Index report which came in at 10.4% on Y/Y basis. Note that housing prices overall continue to decline in the shorter term and have slowed down also on a medium basis across the U.S. as interest rates have risen sharply. The November Consumer Confidence report came in lower at 100.2 during the same time frame. On Wednesday, the Weekly MBA Mortgage Applications Index report which confirmed a .8% drop as the pending home sales report showed a sizable 4.6% fall in October. The Advanced report for international trade in goods showed a $99B deficit in October. The advanced report for retail inventories confirmed a .2% drop in October, while the advanced report for wholesale inventories report came in with an .8% build in October. However, the Q3 GDP was adjusted up to 2.9% , while the GDP Price Deflator was adjusted up to 4.3%. The November Chicago PMI report dropped to 37.2 in November. The JOLTS Job Openings report came in at a 10.334M total in October. The Weekly EIA Crude Oil Inventories conformed a 12.58M/bbl draw. On Thursday, the Personal income report confirmed a .7% rise M/M in October and personal spending report showed a .8% rise. The PCE Price Index report confirmed a .3% M/M rise, while the core-PCE Price Index edged up .2%. The Initial jobless claims report for the week ending November 26 also showed a 16k drop to 225k & the continuing claims report for the week ending November 19 showed a 57k increase to 1.608M. The final IHS Markit Manufacturing PMI reading for November checked in slightly higher at 47.7. The November ISM Manufacturing Index report came in lower at 49% and in contraction territory. The Total construction spending report came in lower by .3% M/M in October. The Total private construction report dropped by .5% M/M. Total public construction spending came in up .6% and on a was up 9.2% on Y/Y basis. Finally, the Weekly EIA Natural Gas Inventories report confirmed a 81 bcf draw. On Friday, the Labor Department’s monthly jobs report for November confirmed that payrolls increased by 263k higher than the 200k mark that was expected, while the unemployment rate remained flat at 3.7%.
With these reports in view, the yield curve pulled back solidly this week with the 2-yr note yield falling by 2o basis points to close at 4.28% & the 10-yr note yield moving down by 20 basis points to close at at 3.49%.on the negative side, oil prices closed higher at $80.13/bbl, jumping 5% this week as stories that OPEC+ would be reducing their production spread widely. However, the US dollar also moved significantly lower down from last Friday’s close of $106.06 to $104.51 and dropping 5% vs. a number of other major currencies and therefore making multinationals’ products a bit more affordable.
As for the major indices, the S&P 500 closed at 4071.70 (+1.13%) for the week with 9 of the 11 sectors closing in the green and is now down 14.7% YTD. 9 of the 11 sectors closed in the green with the communication services sector up +3.3% & the consumer discretionary sector up +2.1% leading all, while the financials and the energy sectors closed in the red. The 6.82% weighting of Apple (AAPL) placed some pressure this week closing at $147.81 moving down .34% over the last 5-days. The Dow 30 closed higher at 34,429.88 (+.24%) and is down 5.25% YTD. The Nasdaq closed at 11,461.50 (+2.09%) for the week and is down 26.74% YTD. In line with the positive bias, the CBOE Volatility Index (^VIX) closed at $19.06, -7.02% over the last 5-days and remains up +10.69% YTD. The small caps on the Russell 2000 also performed well this week and closed at 1,892.84 (+1.27%) & is now down 15.70% YTD. The MicroCaps joined the upward moving party again this week as the iShares Micro-Cap ETF (IWC) closed at $113.98, up 1.43% over the last 5-days and is now down 18.43% YTD.
Did you know that Hong Kong’s main index jumped 27% in November?
BIOTECH AND HEALTHCARE
Biotech stocks jumped higher overall this week. The Nasdaq Biotechnology ETF (IBB) moved up and closed at $138.43, +3.44% over the last 5-days & is down -9.30 YTD. The NYSE ARCA Biotech Index (^BTK) closed at 5,434.06, +4.14% over the last 5-days and is now down 1.53% YTD. The SPDR S&P Biotech ETF (XBI) closed at $85.66, +5.67% over the last 5-days & is now down 23.49% YTD. The 52-week range is is now $61.78-$119.21.
The iShares U.S. Healthcare ETF (IYH) closed at $291.18, +2.17% over the last 5-days and is down -3.06% YTD.
EV, TECH, CONSUMER, FINANCIALS
Apple (AAPL) closed at $147.81, -.20% over the last 5-days. Apple represents a 6.82% weighting in the S&P 500.
EV giant Tesla (TSLA) closed at $194.86,+6.56% over the last 5-days. On Dec. 1, Tesla revealed its Semi, a 18-wheeler long-haul electric freight hauler, which the first will roll out to PepsiCo. (PEP). The Semi has a 500-mile range while hauling 82k pounds of freight according to Tesla.
Shares of JPMorgan (JPM) closed at $135.16, -1.16% over the last 5-days. On December 1, J.P. Morgan announced launched Wealth Plan today, a free digital money coach that gives clients a full picture of their finances and helps them plan, save and invest, all in one place. The experience will be available for free to all 62 million digitally-active Chase customers in the top-ranked Chase Mobile app and Chase.com.
Shares of Amazon.com, Inc. (AMZN) closed $94.13,+.77% over the last 5-days. On December 1, AWS announced an expanded relationship with American Family Insurance, a mutual insurance company focused on property, casualty, business, and life coverage. As part of the multiyear agreement, American Family Insurance has selected AWS as its preferred cloud provider to help accelerate cloud migration, drive innovation, provide financial support and training for the local community, and reduce environmental impact.
Shares of Microsoft Corp. (MSFT) closed at $255.02, +3.04% over the last 5-days. On Nov. 16, Lockheed Martin (LMT) and Microsoft announced a landmark expansion of their strategic relationship to help power the next generation of technology for the Department of Defense (DOD). The game-changing agreement will span four critical areas for the DOD.
Shares of Salesforce, Inc. (CRM) closed at $144.56, -5.73% over the last five days. Salesforce ,the global leader in CRM, announced results for its third quarter fiscal 2023 ended October 31, 2022. Revenue of $7.84 Billion, up 14% Y/Y, up 19% Constant Currency.
Shares of NVIDIA (NVDA), a pioneer in accelerated computing, closed at $168.76, +3.72% over the last 5-days. On Nov. 17, Lockheed Martin (LMT) and NVIDIA announced a collaboration to build an Artificial Intelligence (AI)-driven Earth Observations Digital Twin that will provide the National Oceanic and Atmospheric Administration (NOAA) with an efficient and centralized approach to monitor current global environmental conditions, including extreme weather events.
Cathie Wood’s ARK Innovation ETF (ARKK) closed at $38.16, +6% over the last 5-days.
The Technology Select Sector SPDR Fund (XLK) closed at $135.36, +1.32% over the last 5-days.
Shares of McDonald’s (MCD) closed at $273.40, -.58% over the last 5-days. Reportedly, after a “farewell tour,” the McRib has finally left McDonald’s menus this time apparently for good. McRib, a barbecue pork sandwich was a regular item between 1981 and 1985 and has regularly reappeared as an LTO.
On October 27, McDonald’s Corporation announced results for the third quarter ended September 30, 2022 and highlighted the following: 1) Global comparable sales increased nearly 10%, with growth across all segments, 2) U.S. comparable sales increased more than 6% for the quarter, marking the ninth consecutive quarter of comparable sales growth for the segment, & 3) Digital Systemwide sales* in our top six markets were nearly $7 billion for the quarter, representing over a third of total Systemwide sales in those markets.
GOLD & SILVER
Gold prices closed at $1805/oz., +$47/oz. & silver prices closed at $23.22/oz., +$1.72/oz. for the week.
Hecla Mining (HL) closed at $5.72,+10.42% over the last 5-days & First Majestic (AG) closed at $9.54, +.63% over the last 5-days.
First Majestic announced on Nov. 30 that they had entered into a royalty purchase agreement dated November 25, 2022 to sell a portfolio of its royalty interests (“Royalty Portfolio”) to Metalla Royalty & Streaming Ltd. (NYSE American: MTA) (TSXV: MTA) (“Metalla”) for a total consideration of US$20.0 million (the “Transaction”) in common shares of Metalla.
MEMES CENTRAL
AMC Entertainment (AMC) closed at $8.17, +8.79% & (APE) closed at $.9955, -18.40% over the last 5-days. On Dec. 1., GKIDS, the acclaimed producer and distributor of animation for adult and family audiences, announced it will bring the highly anticipated fourth and final installment of the new theatrical “Rebuild” editions of the EVANGELION franchise, to theaters nationwide. GKIDS, in partnership with Fathom Events, will hold event screenings of the highly anticipated finale on December 6, 8 and 11 only.
GameStop (GME) closed at $27.52, +5.16% over the last 5-days as the shorts lost overall this week. Note that approx. 20% of GME’s outstanding shares are sold short landing it with a short interest ratio of 7.6. GME will report third quarter fiscal 2022 results after the market closes on Wednesday, December 7, 2022.
Seanergy Maritime Holdings Corp. (SHIP) closed at $.5171, -.56% over the last 5-days. On Nov. 30 after the close, SHIP announced its financial results for the third quarter and nine months ended September 30, 2022. The Company also declared a quarterly dividend of $0.025 per share for the third quarter of 2022.
CRYPTO & BITCOIN
Bitcoin (BTC) closed at $17,059.44, up +5.19% over the last 5-days at the time this report was prepared.
ENERGY
The Energy Select Sector SPDR Fund or ETF (XLE) closed at $90.31, -1.70% over the last 5-days. Chevron (CVX) closed at $181.03, -1.45% over the last 5-days. Warren Buffet’s pick in the space, Occidental Petroleum (OXY) closed at $68.21, -2.95% over the last 5-days.
Oil prices closed on Friday to end at $80.13/bbl, up 5% this week.
NEXT WEEK
A full five action packed trading days are back on the agenda again next week.
VP WATCHLIST UPDATES
Please review a select group of emerging names below and their updates below:
- Shares of Natural-Killer cell (NKcell) focused biopharmaceutical firm Fate Therapeutics (FATE) closed at $20.91, +5.45% over the last 5-days.
-
- On Nov. 7, Fate Therapeutics announced that ONO Pharmaceutical Co., Ltd. (ONO) has exercised its option to FT825/ONO-8250, a multiplexed-engineered, iPSC-derived, chimeric antigen receptor (CAR) T-cell product candidate targeting human epidermal growth factor receptor 2 (HER2)-expressing solid tumors. The preclinical product candidate incorporates multiple functional elements to enhance the activity and overcome unique challenges in treating solid tumors with cell-based cancer immunotherapies. “We are encouraged by the compelling preclinical data package generated for FT825/ONO-8250 under our collaboration, which combines the antigen binder that ONO provides and Fate’s industry-leading iPSC product platform to overcome the challenges in solid cancer treatment,” said Toichi Takino, Senior Executive Officer / Executive Director, Discovery & Research of ONO. “We look forward to initiating clinical development of the off-the-shelf, iPSC-derived CAR T-cell product candidate with the aim of delivering benefit to patients with some of the most difficult to treat cancers.”
-
-
November 3, Fate reported business highlights and financial results for the third quarter ended September 30, 2022 with Cash, cash equivalents and investments as of September 30, 2022 were $519.1 million. Scott Wolchko, President and Chief Executive Officer of Fate Therapeutics stated, “We are very pleased with the positive feedback from the FDA under our FT516 RMAT designation in support of our iPSC product platform and potential registrational pathways for the treatment of relapsed / refractory aggressive lymphomas, including for patients who have previously failed CD19-targeted CAR T-cell therapy, and we look forward to engaging the FDA in the fourth quarter to discuss CMC topics in support of pivotal trial readiness. We are also excited to present interim Phase 1 clinical data at the upcoming SITC and ASH conferences, including for our iPSC-derived CAR NK cell programs FT576 in multiple myeloma and FT536 in solid tumors as well as for the first-ever iPSC-derived CAR T-cell program FT819 in B-cell lymphoma. Finally, under our collaboration with Janssen, we are pleased to announce our first IND candidate FT555, a multiplexed-engineered, iPSC-derived CAR NK cell targeting GPRC5D for multiple myeloma, and that Janssen has also exercised its commercial option to an additional product candidate targeting an undisclosed hematologic malignancy antigen.”
-
- Shares of Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need in oncology, with a current focus on breast cancer and radiation-induced lung injury, closed at $.7653, +3.80% over the last 5-days.
-
-
On Nov. 7 after the close, Atossa announced its financial results for the fiscal quarter ended September 30, 2022, and provided an update on recent company developments. Atossa is a clinical-stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet medical need in oncology with a current focus on breast cancer and lung injury caused by cancer treatments. Key developments from Q3 2022 and to date included:
- Received FDA authorization from FDA to initiate its Phase 2 study of neoadjuvant (Z)-endoxifen in premenopausal women with ER+/HER2- breast cancer.
- Invested in a privately-held Dynamic Cell Therapies, a company focused on CAR-T therapies as an important step in pursuing its strategy to develop CAR-T therapies or adjacent opportunities within the immuno-oncology space.
- Completed dosing in both Part B and Part C (of four parts) of Phase 1/2a Clinical Trial of AT-H201 in healthy volunteers, which the Company is now developing for patients with compromised lung function due to the damaging effects of cancer treatment.
-
-
-
On November 1, Atossa announced that it is investing in privately-held developer of CAR-T therapies, Dynamic Cell Therapies, Inc. (DCT), a venture capital backed company that is based in Boston, MA. DCT is in the pre-clinical phase of developing controllable CAR-T cells to address difficult-to-treat cancers. Its platform technology of dynamic control of engineered T-cells is designed to improve the safety, efficacy, and durability of CAR-T cell therapies. This system should find initial applications in hematological cancers, with future approaches in solid tumors and autoimmune diseases. The company’s platform technology uncouples tumor targeting from CAR-T cell activation. Each CAR-T cell recognizes an inert small molecule. This small molecule is conjugated to a tumor-specific antibody. By dosing a small molecule-antibody conjugate, the physician could dynamically control CAR-T cell activity and potentially minimize the risk of life-threatening side effects. Increasing the dose of the small molecule-antibody conjugate should strengthen the immune attack against tumor cells. In addition, the same small molecule can be coupled to different tumor targeting antibodies, allowing the physician to maximize on-target on-tumor efficacy and reduce off-tumor toxicities. To learn more, please visit www.dynamiccelltherapies.com. Steven Quay, M.D., Ph.D., Atossa’s CEO, Chairman and President stated, “This investment in DCT is an important step in pursuing our strategy to develop CAR-T therapies or adjacent opportunities within the immuno-oncology space. We believe that as an active investor in the development of DCT we will be well positioned to evaluate future opportunities while strategically managing our cash position.” Atossa will acquire shares equal to 19.99% of the outstanding capital stock of DCT as of today for a cash payment of $2 million (in addition to $3 million previously paid to DCT). The transaction is expected to close in the fourth quarter.
- On October 25, Atossa announced that it has retained Richard Graydon, M.D., Ph.D. as interim chief medical officer. Dr. Graydon will devote all of his professional time to the Atossa clinical programs. Prior to joining Atossa, Dr. Graydon served as Senior Director of Clinical Development at Johnson and Johnson (JNJ) where he was responsible for leading compound development and clinical trial programs for Janssen Pharmaceuticals. At Janssen, he oversaw the early to late-stage development and the 2022 approval of BCMA-directed CAR T-Cell therapy (cilta-cel) for Multiple Myeloma, as well as daratumumab, imbruvica, siltuximab and other compounds for solid tumor and hematological malignancies. Previously, he held the role of Director of Clinical Development at Daiichi Sankyo, Inc., where he led the early and late-stage development of the small molecule targeted therapy quizartinib for FLT3-positive Acute Myeloid Leukemia. Additionally, he led the early-stage development of the MDM2 inhibitor milademetan in hematological malignancies and liposarcomas. Dr. Graydon spent time in clinical practice following completion of his specialty training in hematology and oncology at Harvard Massachusetts General Hospital. He earned his M.D. and Ph.D. at Stanford University, and undergraduate degree in Chemical Engineering at Cornell University. Dr. Graydon is the author of The Genetic Risks of Cancer: The Effects of DNA, Genomics and Inheritance on Aging and Survival.
-
On Oct. 24, Atossa announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold and authorized initiation of its Phase 2 neoadjuvant clinical study of (Z)-endoxifen in premenopausal women with early-stage estrogen receptor positive (ER+) and human epidermal growth factor receptor 2 negative (HER2-) breast cancer. This is the first study of Atossa’s proprietary (Z)-endoxifen in the United States. At this time, Atossa also announced that it is discontinuing its COVID-19 program (AT-301) so that it can refocus resources on this critical study in breast cancer. “Continuing the development of our proprietary (Z)-endoxifen here in the United States has been a key goal which builds on the recent issuance of a U.S. patent for our proprietary (Z)-endoxifen and results from our Phase 2 “window-of-opportunity” study in Australia,” commented Steven Quay, M.D., Ph.D., Atossa’s CEO, Chairman and President. “We are excited to have engaged Dr. Matthew Goetz, the Erivan K. Haub Family Professor of Cancer Research Honoring Richard F. Emslander, M.D. at Mayo Clinic and Director of the Mayo Clinic Breast Cancer SPORE, as the lead principal investigator for this multi-center study. We look forward to opening the study in the fourth quarter.”
-
- The multi-billion-dollar global fertility market is predicted to reach approximately US$47.9 billion by 2030, yet remains severely underserved with many patients (upwards of 90% by many estimates) unable to access affordable treatment. INVO Bioscience, Inc. (NASDAQ: INVO) offers the INVOcell solution which provides an advanced, effective and affordable infertility treatment to help increase access to care. INVO is commercially advancing INVOcell through the opening of INVO Centers, opportunistically now pursuing acquisitions of established fertility (IVF) clinics in the U.S., and continuing to offer the technology to existing fertility practices. Shares INVO closed at $.8068, and traded up to $.9262, +15.20% in the aftermarket on Friday. The 52-wk range is $.63 – $4.05.
-
-
On Nov. 30, INVO announced the birth of the first baby in Malaysia utilizing the INVOcell solution. The healthy baby boy weighed 3.53 kg and was born on November 11, 2022 at Tuanku Mizan Military Hospital in Kuala Lumpur. Physicians at Advanced Reproductive Centre (ARC), at Hospital Canselor Tuanku Muhriz (HCTM), at the National University of Malaysia conducted the IVC procedure. The patient was part of a prospective peer reviewed study of INVOcell compared to conventional IVF (“cIVF”) that took place at ARC at HCTM. The study, titled “Comparison of Treatment Outcomes among Sibling Oocytes Using Different Culture Systems—Conventional IVF versus INVOcell Device—And Evaluation of INVOcell User Satisfaction: The INVOcIVF Study,” was published in the International Journal of Environmental Research and Public Health. “We couldn’t be more pleased to have been a part of this family’s journey towards parenthood,” commented Steve Shum, CEO of INVO Bioscience. “The INVOcell solution is playing a key role in providing families across the world an alternative method to parenthood by leveraging its innovative medical device to allow fertilization and early embryo development to take place in vivo within the woman’s body; an approach that provides for affordable, high-quality, patient-centered fertility care.” Key findings of the study included:
- The fertilization rate and good embryo quality were comparable (not significantly different) between INVOcell and cIVF.
- Although both methods produce similar fertilization rates and good-quality embryos, the blastulation rates were better in the INVOcell group.
- INVOcell can be used as an alternative method for reproductive treatment in carefully selected patients without jeopardizing outcomes.
- cIVF is costly and not applicable in most rural and district areas, therefore, the INVOcell can be utilized as a cost-effective alternative to cIVF without sacrificing comfort and outcomes.
-
-
- On Monday, November 14, INVO announced financial results for the third quarter ended September 30, 2022 and provided a business update. Revenue (excluding license revenue) was $235,321 compared to $40,303 in the third quarter of the prior year, an increase of 484% and up 61% sequentially compared to the second quarter of 2022. Clinic revenue increased to $176,395, or 370%, compared to the same period last year, and was up 57% sequentially compared to Q2 2022. All reported clinic revenue is derived from the Company’s Atlanta, Georgia-based INVO Center which is consolidated in the financial statements. Revenue from clinics, inclusive of both those accounted for as consolidated and under the equity method, was $450,131, an increase of 1,100% compared to last year and up 111% sequentially compared to the second quarter of 2022. Product sales increased to $58,926 during Q3 2022, an increase of 2,012% compared to the same quarter last year and were up 74% sequentially compared to the second quarter of 2022. INVO has completed due diligence on the previously announced fertility clinic acquisition target and is working to finalize definitive agreements..
-
- ***INSIDER BUYING ALERT***– On Friday June 3, after the close, a number of Form 4’s were filed c. at www.sec.gov confirming that the CEO, COO, CFO and 5 members of the board of directors purchased shares at $.95/share on June 1, 2022. Here’s the link to view all of the share purchases.
-
- On Nov. 10, Chinook provided a business update and reported financial results for the quarter and nine months ended September 30, 2022. “During the third quarter of 2022, we continued advancing our pipeline of clinical and preclinical programs for rare, severe chronic kidney diseases. We are pleased with the strong data presented at ASN Kidney Weekend 2022 from both our lead programs, atrasentan and BION-1301, in IgA nephropathy (IgAN), as well as from CHK-336 and our preclinical research approach,” said Eric Dobmeier, president and chief executive officer of Chinook Therapeutics. “We look forward to 2023, when we plan to initiate a phase 3 study of BION-1301 in patients with IgAN, present data from the ongoing phase 1 clinical trial of CHK-336 in healthy volunteers in the first half and report topline proteinuria data from the ongoing phase 3 ALIGN study of atrasentan in the third quarter.”
- Borqs Technologies, Inc. (Nasdaq: BRQS, $.46), a global provider of 5G wireless solutions, Internet of Things (IoT) solutions, and innovative clean energy, recently provided the following updates on the Company.
-
-
On Dec. 2, Holu Hou Energy, a majority-owned subsidiary of Borqs Technologies announced the launch of a a brand new solar energy storage system designed to share surplus energy across networked units in multi-dwelling units in the Californian market. Using advanced control technology, the solution can improve solar energy utilization and thus lower the barrier to mainstream adoption of solar technology. Holu Hou Energy has piloted and proven that the concept works in Hawaii and now looks to the Californian market which is orders of magnitude larger and well-positioned to leverage the technology. The energy storage system is certified and warrantied as an integrated product, and it includes a modular energy controller that improves resilience, reliability, safety, and performance. It does this by sharing power at the direct current level (DC) which brings the cost of the hardware down and improves compatibility between dwellings. By sharing energy in this way residents can save significantly on energy costs while getting more reliable green energy at the same time. The solution also allows apartment building owners to offer ‘energy as a service’ to their tenants, an arrangement that is set to transform the Californian real estate market. The target market includes residential and commercial PV developers, multi-dwelling unit developers and property managers, homeowners associations, government property managers, commercial property owners and managers, and non-profit organizations.
- Holu Hou Energy President Ted Peck and CEO Brad Hansen bring over 55 years of senior leadership and engineering experience to the table in the public sector and in private company settings, including international careers with Boeing, Applied Materials, and the US Navy. Through their collective experience in the fields of power electronics, energy storage, semiconductors and solar energy, and the Hawaii’s Clean Energy Initiative, this world-class team now offers a new vision of solar energy through their innovative product that can be counted on to provide superior performance, safety and reliability to the rest of America, and eventually – the world.
-
- To view a video clip of a recently completed HHE Multi-Unit Residential project go to: https://www.youtube.com/watch?v=kakbynGM-fQ
Shares of InMed Pharmaceuticals Inc. (INM), a leader in the research, development and manufacturing of rare cannabinoids, closed at $2.74.
- On Nov. 17, Tribe Public’s Webinar Presentation and Q&A Event was co-hosted by Eric A. Adams, CEO & Eric C. Hsu, PhD, Senior Vice President, Pre-Clinical Research & Development of InMed Pharmaceuticals (NASDAQ: INM. They delivered a presentation titled “Exploring The Neuroprotective Qualities of Rare Cannabinoids”& addressed a Q&A session at the end of the presentation. You may now watch the event video art the Tribe Public YouTube Channel at this link.
Thanks again for your attention this week. Please continue to share your thoughts, questions, & ideas as we move forward.
In the meantime, please enjoy the balance of the weekly newsletter’s videos, quotes, updates and let’s find ways to crush it again this year!
Investing & Inspiration
- “No man was ever wise by chance.” – Lucius Annaeus Seneca
- “Progress is man’s ability to complicate simplicity.” – Thor Heyerdahl
- “It is not in the stars to hold our destiny but in ourselves.” – William Shakespeare
-
“It does not matter how slowly you go as long as you do not stop.” – Confucius
-
“I want to put a ding in the universe.” – Steve Jobs
-
“Research is creating new knowledge.” – Neil Armstrong
- “The reward for work well done is the opportunity to do more.” – Jonas Salk
- “Man is a creative retrospection of nature upon itself.” – Karl Wilhelm Friedrich Schlegel
- “There’s something about taking a plow and breaking new ground. It gives you energy.” – Ken Kesey
-
“Success seems to be largely a matter of hanging on after others have let go.” – William Feather
- “The essential conditions of everything you do must be choice, love, passion.” – Nadia Boulanger
-
“More business is lost every year through neglect than through any other cause.” – Rose Kennedy
-
“Give me a lever long enough and a fulcrum on which to place it, and I shall move the world.” – Archimedes
- “A person who won’t read has no advantage over one who can’t read.” – Mark Twain
-
“The best way out is always through.” – Robert Frost
- “Start by doing what’s necessary; then do what’s possible; and suddenly you are doing the impossible.” – Francis of Assisi
-
“Without labor nothing prospers.” – Sophocles
- “Intellectuals solve problems, geniuses prevent them.” – Albert Einstein
-
“This is the precept by which I have lived: Prepare for the worst; expect the best; and take what comes.” – Hannah Arendt
-
“The best and most beautiful things in the world cannot be seen or even touched – they must be felt with the heart.” – Helen Keller
- “He who is brave is free.” – Lucius Annaeus Seneca
-
“When something is important enough, you do it even if the odds are not in your favor.” – Elon Musk
-
“I choose a block of marble and chop off whatever I don’t need.” – Auguste Rodin
-
“Hope is the only bee that makes honey without flowers.” – Robert Green Ingersoll
-
“He who knows that enough is enough will always have enough.” – Lao Tzu
- “Plans to protect air and water, wilderness and wildlife are in fact plans to protect man.” – Stewart Udall
-
“In order to carry a positive action we must develop here a positive vision.” – Dalai Lama
- “A hero is someone who understands the responsibility that comes with his freedom.” – Bob Dylan
- “Inflation destroys savings, impedes planning, and discourages investment. That means less productivity and a lower standard of living.” – Kevin Brady
- “If we give something positive to others, it will return to us. If we give negative, that negativity will be returned.” – Allu Arjun
- “A good plan violently executed now is better than a perfect plan executed next week.” ~ George S. Patton
- “You must do the things you think you cannot do.”- Eleanor Roosevelt
- “Success is dependent on effort.” – Sophocles
- “Nobody who ever gave his best regretted it.” – George Halas
- “Lots of people want to ride with you in the limo, but what you want is someone who will take the bus with you when the limo breaks down.” ~ Oprah Winfrey
- “And when I breathed, my breath was lightning.” – Black Elk
- “Moderation is the silken string running through the pearl chain of all virtues.” – Joseph Hall
- “You are the sum total of everything you’ve ever seen, heard, eaten, smelled, been told, forgot – it’s all there. Everything influences each of us, and because of that I try to make sure that my experiences are positive.” – Maya Angelou
- “If you want a guarantee, buy a toaster.” – Clint Eastwood
- “We are an impossibility in an impossible universe.” – Ray Bradbury
- “If you think in terms of a year, plant a seed; if in terms of ten years, plant trees; if in terms of 100 years, teach the people.” – Confucius
- “I’d rather attempt to do something great and fail than to attempt to do nothing and succeed.” – Robert H. Schuller
- “Do your little bit of good where you are; it’s those little bits of good put together that overwhelm the world.” Desmond Tutu
- “It takes considerable knowledge just to realize the extent of your own ignorance.” – Thomas Sowell
- “Do not dwell in the past, do not dream of the future, concentrate the mind on the present moment.” – Buddha”
- Surprise is the greatest gift which life can grant us.” – Boris Pasternak
- “Trust in dreams, for in them is hidden the gate to eternity.” – Khalil Gibran
- “Always be yourself, express yourself, have faith in yourself, do not go out and look for a successful personality and duplicate it.” – Bruce Lee
- “All life is an experiment. The more experiments you make the better.” – Ralph Waldo Emerson
- “There are no secrets to success. It is the result of preparation, hard work, and learning from failure.” – Colin Powell
- “There is more to life than increasing its speed.” – Mahatma Gandhi
- “Your attitude is like a box of crayons that color your world. Constantly color your picture gray, and your picture will always be bleak. Try adding some bright colors to the picture by including humor, and your picture begins to lighten up.” – Allen Klein
- “Definiteness of purpose is the starting point of all achievement.” – W. Clement Stone
- “Success usually comes to those who are too busy to be looking for it.” – Henry David Thoreau
- “In matters of truth and justice, there is no difference between large and small problems, for issues concerning the treatment of people are all the same.” – Albert Einstein
- “Life is too short for long-term grudges.” – Elon Musk
- “There cannot be a crisis next week. My schedule is already full.” – Henry Kissinger
- “Success consists of getting up just one more time than you fall.” – Oliver Goldsmith
- “The Earth is the cradle of humanity, but mankind cannot stay in the cradle forever.” – Konstantin Tsiolkovsky
- “Ours is a world of nuclear giants and ethical infants. We know more about war that we know about peace, more about killing that we know about living.” – Omar N. Bradley
- “Beauty surrounds us, but usually we need to be walking in a garden to know it.” – Rumi
- “But man is not made for defeat. A man can be destroyed but not defeated.” – Ernest Hemingway
- “Don’t watch the clock; do what it does. Keep going.” – Sam Levenson
- “Let there be work, bread, water and salt for all.” – Nelson Mandela
- “The social object of skilled investment should be to defeat the dark forces of time and ignorance which envelope our future.” – John Maynard Keynes
- “A successful society is characterized by a rising living standard for its population, increasing investment in factories and basic infrastructure, and the generation of additional surplus, which is invested in generating new discoveries in science and technology.” – Robert Trout
- “I know not with what weapons World War III will be fought, but World War IV will be fought with sticks and stones.” – Albert Einstein
- “It is the fight alone that pleases us, not the victory.” – Blaise Pascal
- “If you can’t describe what you are doing as a process, you don’t know what you’re doing.” – W. Edwards Deming
- “Never interrupt your enemy when he is making a mistake.” – Napoleon Bonaparte
- “Be sure you put your feet in the right place, then stand firm.” – Abraham Lincoln
- “Without investment there will not be growth, and without growth there will not be employment.” – Muhtar Kent
- “You have to do your own growing no matter how tall your grandfather was.” – Abraham Lincoln
- “Victory has a thousand fathers, but defeat is an orphan.” – John F. Kennedy
- “Delete the negative; accentuate the positive!” – Donna Karan
- “It’s crazy how fast time flies and how things progress.” – Nathan Chen
- “The world is a dangerous place to live; not because of the people who are evil, but because of the people who don’t do anything about it.” – Albert Einstein
- “Life isn’t about finding yourself. Life is about creating yourself.” – George Bernard Shaw
- “Everything has beauty, but not everyone sees it.” – Confucius
- “A man must be big enough to admit his mistakes, smart enough to profit from them, and strong enough to correct them.” – John C. Maxwell
- “Walking with a friend in the dark is better than walking alone in the light.” – Helen Keller
- “A man who dares to waste one hour of time has not discovered the value of life.” – Charles Darwin
- “The greater danger for most of us lies not in setting our aim too high and falling short; but in setting our aim too low, and achieving our mark.” – Michelangelo
- “Progress is man’s ability to complicate simplicity.” – Thor Heyerdahl
- “I like to encourage people to realize that any action is a good action if it’s proactive and there is positive intent behind it.” – Michael J. Fox
- “Nothing is impossible, the word itself says ‘I’m possible’!” – Audrey Hepburn
- “But investment in space stimulates society, it stimulates it economically, it stimulates it intellectually, and it gives us all passion.” – Bill Nye
- “Bitcoin, in the short or even long term, may turn out be a good investment in the same way that anything that is rare can be considered valuable. Like baseball cards. Or a Picasso.” – Andrew Ross Sorkin
- “Life is a tragedy when seen in close-up, but a comedy in long-shot.” – Charlie Chaplin
- “No matter what you’re going through, there’s a light at the end of the tunnel and it may seem hard to get to it but you can do it and just keep working towards it and you’ll find the positive side of things.” – Demi Lovato
- “Infrastructure investment in science is an investment in jobs, in health, in economic growth and environmental solutions.” – Oren Etzioni
- “Educating our children and giving them the skills they need to compete in a global economy is a smart investment in our country’s future.” – Sheldon Whitehouse
- “Know thy self, know thy enemy. A thousand battles, a thousand victories.” – Sun Tzu
- “If one does not know to which port one is sailing, no wind is favorable.” – Lucius Annaeus Seneca
- “Beware of missing chances; otherwise it may be altogether too late some day.” – Franz Liszt
- “The sofa is a really important investment for anybody, and I don’t mean financially. You need to find a really great sofa that can transition with you, and you can build from there.” – Jeremiah Brent
- “There is no investment you can make which will pay you so well as the effort to scatter sunshine and good cheer through your establishment.” – Orison Swett Marden
- “Nothing in life is to be feared, it is only to be understood. Now is the time to understand more, so that we may fear less.” – Marie Curie
- “There is little that can withstand a man who can conquer himself.” – Louis XIV
- “In tennis, you strike a ball just after the rebound for the fastest return. It’s the same with investment.” – Masayoshi Son
- “A camel makes an elephant feel like a jet plane.” – Jackie Kennedy
- “The advance of technology is based on making it fit in so that you don’t really even notice it, so it’s part of everyday life.” – Bill Gates
- “Success depends upon previous preparation, and without such preparation there is sure to be failure.” – Confucius, Chinese
- “Coming together is a beginning; keeping together is progress; working together is success.” – Edward Everett Hale
- “Never do anything against conscience even if the state demands it.”– Albert Einstein
- “Education is not only a ladder of opportunity, but it is also an investment in our future.” – Ed Markey
- “The true measure of a man is how he treats someone who can do him absolutely no good.” – Samuel Johnson
- “In my view, the biggest investment risk is not the volatility of prices, but whether you will suffer a permanent loss of capital. Not only is the mere drop in stock prices not risk, but it is an opportunity. Where else do you look for cheap stocks?” – Li Lu
- “A successful society is characterized by a rising living standard for its population, increasing investment in factories and basic infrastructure, and the generation of additional surplus, which is invested in generating new discoveries in science and technology.” – Robert Trout
- “The best preparation for tomorrow is doing your best today.” – H. Jackson Brown, Jr.
- “Friendship marks a life even more deeply than love. Love risks degenerating into obsession, friendship is never anything but sharing.” – Elie Wiesel
- “Investing in women’s lives is an investment in sustainable development, in human rights, in future generations – and consequently in our own long-term national interests.” – Liya Kebede
- “Success isn’t measured by money or power or social rank. Success is measured by your discipline and inner peace.” – Mike Ditka
- “No matter how many goals you have achieved, you must set your sights on a higher one.” – Jessica Savitch
- “Start where you are. Use what you have. Do what you can.”– Arthur Ashe
- “The secret of getting ahead is getting started.” – Mark Twain
- “The amount of work and the amount of both physical and emotional investment it takes to get to the top.” – Drew Bledsoe
Videos
Post View Count : 501